Article

Biophysical Properties and Oxygenation Potential of High-Molecular-Weight Glutaraldehyde-Polymerized Human Hemoglobins Maintained in the Tense and Relaxed Quaternary States

William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio 43210, USA.
Tissue Engineering Part A (Impact Factor: 4.64). 10/2010; 17(7-8):927-40. DOI: 10.1089/ten.TEA.2010.0353
Source: PubMed

ABSTRACT

Recent clinical evaluation of commercial glutaraldehyde-polymerized hemoglobins (PolyHbs) as transfusion solutions has demonstrated several adverse side effects. Chief among these is the hypertensive effect. Fortunately, previous studies have shown that the hypertensive effect can be attenuated by removing free hemoglobin (Hb) and low-molecular-weight (low-MW) PolyHbs from the PolyHb mixture. In this work, polymerized human Hb (PolyhHb) solutions were synthesized in two distinct quaternary states with high MW and subjected to extensive diafiltration to remove free Hb and low-MW PolyhHb components (<500 kDa). The resultant PolyhHb solutions possessed high MW, distinct quaternary state, distinct reactivities with O(2) and CO, similar NO deoxygenating rate constants, distinct autoxidation rate constants, high viscosity, and low colloid osmotic pressure. To preliminarily assess the ability of PolyhHb solutions to oxygenate surrounding tissues fed by a blood vessel, we evaluated the ability of PolyhHbs to transport O(2) to cultured hepatocytes in a mathematical model of a hollow fiber bioreactor. The structure of individual hollow fibers in the bioreactor is similar to that of a blood vessel and provides an easy way to assess the oxygenation potential of PolyhHbs without the need for expensive and time-consuming animal studies. It was observed that PolyhHbs with low O(2) affinities were more effective in oxygenating cultured hepatocytes inside the bioreactor than high O(2) affinity PolyhHbs. Taken together, our results show that it is possible to synthesize high-MW PolyhHbs with no free Hb and low-MW PolyhHb components that are capable of transporting O(2) to cultured cells/tissues.

Download full-text

Full-text

Available from: Pedro Cabrales
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bovine hemoglobin microparticles (Hb-MPs) as suitable oxygen carriers are fabricated easily by three key steps: coprecipitation of Hb and CaCO(3) to make Hb-CaCO(3)-microparticles (Hb-CaCO(3)-MPs), cross-linking by glutaraldehyde (GA) to polymerize the Hb and dissolution of CaCO(3) template to obtain pure Hb-MPs. The Hb entrapment efficiency ranged from 8 to 50% corresponding to a hemoglobin quantity per Hb-MP of at least one-third of that in one erythrocyte. The Hb-MPs are spherical, with an average diameter of 3.2 μm and high oxygen affinity. The methemoglobin level was increased after preparation, but can be reduced to less than 7% with ascorbic acid. Phagocytosis assays showed low immunogenicity of Hb-MPs if the particles were cross-linked with low concentration of GA and treated with sodium borohydride. Magnetite-loaded Hb-MPs circulated up to 4 days after intravenous application.
    Full-text · Article · Sep 2012 · Biomacromolecules
  • [Show abstract] [Hide abstract]
    ABSTRACT: There have been at least two major concerns with use of HBOCs as resuscitation fluids for traumatic hemorrhage: potential coagulopathy and interference with conventional clinical laboratory coagulation measurements.
    No preview · Chapter · Jan 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hemoglobin (Hb)-based oxygen (O2) carriers (HBOCs) are continuously being optimized as red blood cell (RBC) substitutes in order to overcome the well-known side-effects that are associated with transfusion of cell-free Hb (Alayash 1999, 2004). These side-effects include vasoconstriction, systemic hypertension and oxidative tissue toxicity (Alayash 1999, 2004). It is hypothesized that these side-effects are due to HBOC extravasation into the tissue space and the NO scavenging ability of cell-free Hb (Suaudeau et al. 1979; Nakai et al. 1998; Dull et al. 2004; Liu et al. 1998; Liao et al. 1999). Polymerized HBOCs (PolyHbs) were thus engineered with molecular sizes larger than that of cell-free Hb, with the goal of reducing extravasation of the HBOC from the vascular space into the tissue space (Alayash 2004; Palmer 2006). This approach should reduce the proximity of the HBOC to the endothelium, which in turn should reduce/eliminate the aforementioned side-effects (Alayash 2004; Palmer 2006). In order to address this need for large sized HBOCs compared to cell-free Hb, the following commercial PolyHbs were initially developed: Oxyglobin® (OPK Biotech LLC, Cambridge, MA), Hemopure® (OPK Biotech LLC, Cambridge, MA), PolyHeme® (Northfield Laboratories Inc., Evanston, IL) and Hemolink™ (Hemosol Inc., Toronto, Canada) (OPK Biotech 2012; Rentko et al. 2006; Day 2003; Adamson and Moore 1998). However, these commercial products still elicited the aforementioned side-effects and are coincidentally close together in molecular weight (MW) (Rentko et al. 2006; Day 2003; Adamson and Moore 1998; Tsai et al. 2006; Butt et al. 2010, 2011; Kasper et al. 1996; LaMuraglia et al. 2000; Jahr et al. 2008; Freilich et al. 2009; Yu et al. 2010; Handrigan et al. 2005; Cheng et al. 2004; Greenburg and Kim 2004; Hill et al. 2002; Lieberthal et al. 1999). In the case of Oxyglobin®, its' side-effects were directly attributed to PolyHb extravasation from the blood vessel lumen into the tissue space Butt et al. (2010; 2011). Therefore, the ultrahigh MW HBOC Oxyvita™ (OXYVITA Inc., New Windsor, NY) was developed, which did not extravasate and induce significant vasoconstriction or hypertension (OXYVITA Inc. 2012; Matheson et al. 2002; Bucci et al. 2007; Jia and Alayash 2009). However, Oxyvita® has a high O2 affinity so it is unclear how well it will deliver O2 in vivo, despite its lack of vascular side-effects (Matheson et al. 2002; Jia and Alayash 2009). It is interesting to note that these commercial PolyHbs differ in MW by several orders of magnitude, and until recently there has been no systematic study of PolyHb MW on its' in vivo safety profile (Rentko et al. 2006; Day 2003; Adamson and Moore 1998; Matheson et al. 2002; Bucci et al. 2007; Jia and Alayash 2009). To address this deficit in the literature, recent studies have shed light on the relationship between PolyHb molecular size and its' in vivo safety profile (Cabrales et al. 2009; Cabrales et al. 2010; Baek et al. 2012). These studies demonstrate that increasing the molecular size of tense (T)-state bovine PolyHb reduces vasoconstriction, systemic hypertension, and oxidative tissue toxicity (Cabrales et al. 2009, 2010; Baek et al. 2012). Therefore, it is expected that further work in this area will lead to the optimization of PolyHb size in order to improve its in vivo safety profile for eventual human use.
    No preview · Article · Oct 2014
Show more